Premier Research Acquires Camargo Pharmaceutical Services to Enhance Global Drug Development Capabilities
On May 18, 2021, Premier Research officially acquired Camargo Pharmaceutical Services (hereinafter referred to as “Camargo”), a pharmaceutical services company based in Cincinnati, United States.
Camargo is a global leading pharmaceutical services company specializing in drug development services for emerging biopharmaceutical companies. Through this acquisition of Camargo, Premir Pharma will achieve deeper knowledge coverage and a higher level of professional expertise in the pharmaceutical services sector, enabling it to provide reliable support to clients across all stages of product development. This integration will also expand Premir’s service team and broaden the scope of its specialized business areas. In the future, Premir will be better positioned to help clients address unmet patient needs in clinical practice across various medical conditions.
The two parties forging this powerful alliance are Premir Pharma, a global leading CRO company providing strategic and regulatory consulting services as well as clinical development services for the biotechnology, specialized pharmaceuticals, and medical device industries; and Camargo, a global leading strategic, regulatory, and commercial partner for emerging biopharmaceutical companies, which boasts extensive experience in navigating challenging drug development programs and accelerated approval pathways, with particular expertise in the development of oncology, pediatrics, rare diseases, and 505(b)(2) products.
The merger is undoubtedly welcome news for clients across all sectors, both from past collaborations and upcoming partnerships. This integration will enhance and elevate the two companies’ comprehensive capabilities in product planning, product development, and differentiated services, thereby delivering superior quality service to customers.
Dr. Sameena Sharif, President of the RPI Division at Pumeier Pharmaceuticals“We are highly confident in this acquisition, which will enable us to deliver deeper knowledge coverage and a more advanced professional framework, providing reliable support to clients at every stage of their product development. Camargo’s well-regarded services in regulatory affairs, non-clinical development, and patient-centric product differentiation will add significant value to our strategic and development consulting services, which we have been delivering for the past 25 years.”
Dan Duffy, CEO of Camargo“Premier Pharma, as a full-service CRO provider, has provided Camargo with the strong momentum needed to strengthen its long-term development strategy. Premier Pharma’s well-deserved reputation and capabilities in supporting its clients, particularly those in the rare disease and oncology sectors, will help accelerate our joint growth in the specialty pharmaceutical space.”
Camargo Pharmaceutical Services, founded in 2003, is a leading global strategic, regulatory, and commercial partner for emerging biopharmaceutical companies, with clients in more than 35 countries worldwide. Camargo has been dedicated to serving rare and challenging development projects where no established playbook exists, relying on integrated solutions to help clients achieve their goals efficiently and cost-effectively. For more information, please visit the Camargo website: camargopharma.com.
Pumir Pharma is a leading clinical research and development service provider, operating in 84 countries worldwide. It is dedicated to helping biotechnology companies and specialized innovative pharmaceutical firms translate their innovative ideas into practice in new drug development. Whether formulating product lifecycle strategies, shortening clinical development cycles, acquiring patient data, providing global regulatory affairs consulting, or offering expertise in specific therapeutic areas, Pumir Pharma is committed to helping customers address unmet patient needs across a wide range of medical conditions.